{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:41:08Z","timestamp":1793194868266,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009741","name":"National Blood Foundation","doi-asserted-by":"publisher","award":["NBF 22-09R"],"award-info":[{"award-number":["NBF 22-09R"]}],"id":[{"id":"10.13039\/100009741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010462","name":"National Institute of Genetics","doi-asserted-by":"publisher","award":["18A2023"],"award-info":[{"award-number":["18A2023"]}],"id":[{"id":"10.13039\/501100010462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL164016-01A1"],"award-info":[{"award-number":["HL164016-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL157975-01A1"],"award-info":[{"award-number":["HL157975-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL144552"],"award-info":[{"award-number":["HL144552"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["23CDA1053102"],"award-info":[{"award-number":["23CDA1053102"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jtha.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:23:30Z","timestamp":1739636610000},"page":"1596-1607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preventative and therapeutic effects of a novel humanized anti-glycoprotein Ib\u03b1 fragment of antigen-binding region in a\u00a0murine model of thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0120-9343","authenticated-orcid":false,"given":"Liang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reheman","family":"Adili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.D.","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sladjana","family":"Slavkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong Ruby","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyu","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1680-5295","authenticated-orcid":false,"given":"X. Long","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.02.009_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-med-061813-013241","article-title":"ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura","volume":"66","author":"Zheng","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtha.2025.02.009_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.02.009_bib3","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura","volume":"91","author":"Furlan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.ATV.0000058401.34021.D4","article-title":"Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura","volume":"23","author":"Tsai","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.02.009_bib5","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","article-title":"ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions","volume":"100","author":"Dong","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib6","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2009-01-195461","article-title":"Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site","volume":"114","author":"Raife","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib7","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.113.006727","article-title":"Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy","volume":"129","author":"Tersteeg","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.02.009_bib8","doi-asserted-by":"crossref","first-page":"11552","DOI":"10.1073\/pnas.192448999","article-title":"A\u00a0new name in thrombosis, ADAMTS13","volume":"99","author":"Sadler","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2025.02.009_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.009_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib11","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib12","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.009_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.009_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-138-2-200301210-00011","article-title":"Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab","volume":"138","author":"Zheng","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.02.009_bib16","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/jth.15406","article-title":"The standard of care for immune thrombotic thrombocytopenic purpura today","volume":"19","author":"Zheng","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib17","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/jth.15892","article-title":"Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: post-HERCULES study","volume":"20","author":"Scully","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A\u00a0regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbrc.2021.06.030","article-title":"High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP","volume":"567","author":"Lee","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jtha.2025.02.009_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/09537104.2021.1922883","article-title":"Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet\u00a0count during treatment with caplacizumab","volume":"33","author":"Ditzel","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2025.02.009_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1160\/TH07-10-0629","article-title":"Clearance of von Willebrand factor","volume":"99","author":"Denis","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib23","first-page":"1182","article-title":"Integrated genomic analysis identifies ANKRD36 gene as a novel and common biomarker of disease progression in chronic myeloid leukemia","volume":"10","author":"Iqbal","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.jtha.2025.02.009_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/bloodadvances.2016000711","article-title":"Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura","volume":"1","author":"Zheng","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.02.009_bib25","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/ATVBAHA.118.311407","article-title":"Transfusion of platelets loaded with recombinant ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats-13) is efficacious for inhibiting arterial thrombosis associated with thrombotic thrombocytopenic purpura","volume":"38","author":"Abdelgawwad","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.02.009_bib26","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/bloodadvances.2023011617","article-title":"Targeting neutrophil extracellular trap accumulation under flow in patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"8","author":"Yada","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.02.009_bib27","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1161\/ATVBAHA.119.312848","article-title":"Formation and resolution of pial microvascular thrombosis in a mouse model of thrombotic thrombocytopenic purpura","volume":"39","author":"Adili","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.02.009_bib28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2025.02.009_bib29","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood.2019001040","article-title":"Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy","volume":"134","author":"Zheng","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2019.237396","article-title":"Histone-induced thrombotic thrombocytopenic purpura in adamts13-\/- zebrafish depends on von Willebrand factor","volume":"105","author":"Zheng","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.02.009_bib31","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood.V73.8.2074.2074","article-title":"Multimeric composition of endothelial cell-derived von Willebrand factor","volume":"73","author":"Tsai","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0049-3848(95)00130-J","article-title":"Effect of TNF-alpha, Shiga toxin and calcium ionophore on Weibel-Palade body content of endothelial cells: possible implications for the hemolytic uremic syndrome","volume":"79","author":"Kaye","year":"1995","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.009_bib33","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1172\/JCI26007","article-title":"Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice","volume":"115","author":"Motto","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2025.02.009_bib34","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","article-title":"A\u00a0new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13","volume":"119","author":"Schiviz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib35","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/jth.14407","article-title":"Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols","volume":"17","author":"McDaniel","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00313029700169385","article-title":"Hemolytic uremic syndrome following taipan envenomation with response to plasmapheresis","volume":"29","author":"Cobcroft","year":"1997","journal-title":"Pathology"},{"key":"10.1016\/j.jtha.2025.02.009_bib37","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jtha.2024.02.003","article-title":"Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura","volume":"22","author":"Zheng","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib38","first-page":"2993","article-title":"Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura","volume":"141","author":"Halkidis","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib39","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.jtha.2023.02.011","article-title":"Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura","volume":"21","author":"Underwood","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.009_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1146\/annurev.med.53.082901.103948","article-title":"Thrombotic thrombocytopenic purpura: the systemic clumping \u201cplague.\u201d","volume":"53","author":"Moake","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtha.2025.02.009_bib42","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1537-2995.2009.02232.x","article-title":"Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura","volume":"49","author":"Kn\u00f6bl","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2025.02.009_bib43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1160\/TH10-08-0520","article-title":"Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura","volume":"105","author":"Jilma-Stohlawetz","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib44","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"Cataland","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.02.009_bib45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH13-06-0490","article-title":"Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in\u00a0vitro and in\u00a0vivo in murine models of thrombosis","volume":"111","author":"Lei","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.009_bib46","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1111\/bph.13178","article-title":"A\u00a0novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury","volume":"172","author":"Li","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jtha.2025.02.009_bib47","article-title":"NETosis is critical in patients with severe community-acquired pneumonia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.02.009_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.32607\/actanaturae.11503","article-title":"Neutrophil extracellular traps (NETs): opportunities for targeted therapy","volume":"13","author":"Volkov","year":"2021","journal-title":"Acta Naturae"},{"key":"10.1016\/j.jtha.2025.02.009_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.708302","article-title":"NETosis and the immune system in COVID-19: mechanisms and potential treatments","volume":"12","author":"Gillot","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2025.02.009_bib50","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.7150\/ijms.53728","article-title":"Neutrophil extracellular traps (NETs) and vasculitis","volume":"18","author":"Arneth","year":"2021","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jtha.2025.02.009_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11926-020-00977-6","article-title":"NETosis in rheumatic diseases","volume":"23","author":"Jariwala","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"3825\u20139","key":"10.1016\/j.jtha.2025.02.009_bib52","first-page":"S1","article-title":"AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura","volume":"121","author":"Jin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib53","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood-2010-02-271957","article-title":"Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice","volume":"116","author":"Huang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib54","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1182\/blood-2011-06-363648","article-title":"Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways","volume":"118","author":"Liu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.02.009_bib55","first-page":"195","article-title":"Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies","volume":"6","author":"Keir","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jtha.2025.02.009_bib56","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.jtha.2025.02.009_bib57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/jth.12226","article-title":"Clearance of von Willebrand factor","volume":"11","author":"Casari","year":"2013","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625000741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625000741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:27:23Z","timestamp":1778617643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625000741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1538783625000741"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.009","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventative and therapeutic effects of a novel humanized anti-glycoprotein Ib\u03b1 fragment of antigen-binding region in a\u00a0murine model of thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}